Type Size

    A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength

    The aim of this study was to determine the skeletal effects of systemic administration of a soluble bone morphogenetic protein type1A receptor fusion protein (mBMPR1A-mFc) in vivo.  mBMPR1A-mFc was found to bind BMP2/4 specifically and with high affinity and prevent downstream signaling. mBMPR1A-mFc treatment of immature and mature mice increased bone mineral density, cortical thickness, trabecular bone volume, thickness and number, and decreased trabecular separation.  Histologically, mBMPR1A-mFc was found to increase osteoblastic bone formation and decreases bone resorption, producing an increase in bone mass.


    Baud'huin M, Solban N, Cornwall-Brady M, Sako D, Kawamoto Y, Liharska K, et al

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details